X

Drug Profile

Research programme: cardiovascular disorders therapies - AbbVie

Alternative Names: SLV316; SLV329; SLV335; SLV344; SLV345; SLV346; SLV352; SLV356

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Solvay
Developer AbbVie
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Cardiovascular disorders

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Europe
02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
23 Mar 2010 Preclinical development of SLV 342, SLV 352, SLV 356 & SLV 358 is ongoing

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com